New drug cocktail aims to clear stubborn hand and foot pustules
NCT ID NCT07530367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether combining two drugs, tofacitinib and imatinib, can safely clear the painful pustules of palmoplantar pustulosis (PPP), a rare chronic skin disease on the palms and soles. About 135 adults with moderate-to-severe PPP will receive either the combo or a placebo for 16 weeks. The main goal is to see if at least 90% of the skin improves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib and imatinib
What this could lead to
If it works, this could provide the first approved treatment for palmoplantar pustulosis, significantly clearing skin lesions on hands and feet.
What could go wrong
This is an early-stage Phase 3 trial with only 135 participants. The combination therapy may cause side effects or fail to show better results than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••